Vanguard Capital Management LLC has revealed a significant investment in Immunome Inc., according to a recent SEC filing. The firm now holds 5.04% of Immunome's common stock, amounting to 5,725,578 shares. This disclosure is noteworthy as it indicates Vanguard's growing influence in the pharmaceutical preparations sector.

Immunome Inc., based in Bothell, Washington, is a company focused on developing innovative therapies in the pharmaceutical space. The firm operates under the SIC code for Pharmaceutical Preparations, which encompasses a wide range of drug development and manufacturing activities.

The filing, dated October 30, 2026, provides specific details about Vanguard's ownership. The report states that Vanguard has sole voting power over 843,447 shares and sole dispositive power over the entire 5,725,578 shares. This level of ownership positions Vanguard as a significant player in Immunome's corporate governance.

The impact of this filing may extend to various stakeholders, including Immunome's management and existing shareholders. With Vanguard's substantial stake, the company may face increased scrutiny and pressure regarding its strategic decisions and performance. Additionally, this investment could encourage other institutional investors to consider similar positions in Immunome.

As for what’s next, the filing does not specify any forthcoming actions or events related to this investment. However, Vanguard's active management of its holdings suggests that further developments may arise as the situation evolves.